About the Company
89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ETNB News
89bio Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and ...
89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ...
Warning! GuruFocus has detected 2 Warning Sign with ETNB. On February 29, 2024, 89bio Inc (NASDAQ:ETNB) released its 8-K filing, detailing the financial results for the fourth quarter and full ...
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic ...
Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come
A rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca ...
89bio to Participate in the Leerink Partners Global Biopharma Conference
SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies ...
Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs
That has created significant uncertainty for biotech companies such as Akero Therapeutics and 89bio, which focus on targeting MASH directly through a class of drugs known as FGF21. But these ...
89bio Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Madrigal’s stock surges as FDA approves first drug for liver disease MASH
Madrigal Pharmaceuticals on Thursday received the FDA’s first approval of a drug designed to treat a severe liver disease ...
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, ...
89bio, Inc.: 89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic ...
Loading the latest forecasts...